retatrutide phase 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Lilly's triple agonist achieves 16.8%

Litigation between Novo, Mylan and Viatris and Sun Pharmaceutical Industries with respect to the patents protecting Wegovy is still ongoing

The firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area

Testing may include purity verification, LCMS screening, heavy metals analysis, endotoxin analysis, and sterility testing

Both medications slow gastric emptying so meals stay with you longer, dampen hunger and food noise through signals to the hypothalamus, and improve insulin response

[1] Patients with well-controlled hypothyroidism secondary to Hashimoto's disease who are stable on levothyroxine replacement therapy may be considered for Wegovy treatment, provided they meet the eligibility criteria for weight management therapy

16 weeks (avg 9 mg/week) 15 vials 144 mg total needed